Compare Novagold Resources Inc. (NG) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novagold Resources Inc. vs Novartis AG — how do they compare? Novagold Resources Inc. trades at $6.32 (market cap $2.90B), while Novartis AG trades at $148.12 (market cap $271.82B). The key difference: Novartis AG is far larger — about 93.7× Novagold Resources Inc.'s market cap, and Novartis AG pays a 3.33% dividend while Novagold Resources Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novagold Resources Inc. for 0 Days and Novartis AG for 82 Days on average.
| NG | NVS | |
|---|---|---|
Market Cap | $2.90B | $271.82B |
Volume | 3,973,464 | 1,841,354 |
Sector | Basic Materials | Health |
52-Week High | $14.20 | $168.62 |
52-Week Low | $5.18 | $121.80 |
Typical Hold Time | 0 Days | 82 Days |
Enterprise Value | $2.74B | $313.15B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NovaGold Resources (NG) trades at $6.63, down 1.49% today, as the company navigates its development phase for the Donlin Gold project. The stock shows mixed earnings performance with recent quarterly losses but beats expectations in two of the last four quarters. Financials reveal negative profitability metrics with ROE at -32.81% and net income of -$94.66M for 2025, though cash flow remains positive due to financing activities. Recent news highlights the company's move to acquire full ownership of Donlin Gold, a major Alaska gold project.
The outlook for NG hinges on successful development of Donlin Gold, with 100% analyst buy ratings signaling strong Wall Street confidence. However, significant execution risks exist given negative earnings and substantial capital requirements. Investors face volatility from gold price fluctuations and project development timelines, making this suitable for those with high risk tolerance seeking exposure to a major gold development story.
NVS trades at $146.88, up 2.11% today, with a bearish technical signal from moving averages and an overbought RSI. The company reported revenue of $56.67B in 2025, with a net income margin of 22.5%, and recently announced a $7.8B licensing deal with China's Abogen for RNA-based therapy. Earnings have been mixed, beating in Q4 2025 and Q2 2026 but missing in Q1 2026.
The outlook is cautious due to recent clinical trial setbacks and investor scrutiny of M&A strategy. Analyst consensus is a $146 price target with a hold-heavy rating. Risks include pipeline failures and competitive pressures, but strong cash flow and profitability provide support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novagold Resources Inc.
NovaGold Resources Inc. is a mineral exploration and development company that holds a majority interest in the Donlin Gold project, an undeveloped gold deposit in Alaska.
Read more on NG →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
